Publication Name	World Journal of Clinical Oncology
Manuscript ID	64954
Country	Argentina

Received	2021-02-25 17:21
Peer-Review Started	2021-02-25 17:30
To Make the First Decision
Return for Revision	2021-05-04 02:36
Revised	2021-05-10 22:12
Second Decision	2021-06-25 13:50
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2021-06-25 14:16
Articles in Press	2021-06-25 14:16
Publication Fee Transferred
Edit the Manuscript by Language Editor	2021-07-01 20:06
Typeset the Manuscript	2021-07-19 07:07
Publish the Manuscript Online	2021-07-21 09:30

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Esophagogastric junction adenocarcinoma: Preoperative chemoradiation or perioperative chemotherapy?
Manuscript Source	Invited Manuscript
All Author List	Francisco Laxague and Francisco Schlottmann
Funding Agency and Grant Number
Corresponding Author	Francisco Schlottmann, MD, Surgeon, Department of Surgery, Hospital Alemán of Buenos Aires, Av. Pueyrredón 1640, Buenos Aires 1118, Argentina. fschlottmann@hotmail.com
Key Words	Esophageal cancer; Esophagogastric junction tumor; Esophageal Adenocarcinoma; Chemotherapy; Chemoradiation; Neoadjuvant therapy.
Core Tip	Surgical treatment only has shown poor results in patients with locally advanced esophagogastric junction tumors. Perioperative chemotherapy and neoadjuvant chemoradiation are valid treatment modalities for these patients. This evidence-based review explores the results, advantages, and disadvantages of both approaches. In addition, future directions with potentially effective novel drugs are also discussed.
Publish Date	2021-07-21 09:30
Citation	Laxague F, Schlottmann F. Esophagogastric junction adenocarcinoma: Preoperative chemoradiation or perioperative chemotherapy? World J Clin Oncol 2021; 12(7): 557-564
URL	https://www.wjgnet.com/2218-4333/full/v12/i7/557.htm
DOI	https://dx.doi.org/10.5306/wjco.v12.i7.557

Full Article (PDF)	WJCO-12-557.pdf
Full Article (Word)	WJCO-12-557.docx
Manuscript File	64954_Review-FilipodiaCL.docx
Answering Reviewers	64954-Answering reviewers.pdf
Audio Core Tip	64954-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	64954-Conflict-of-interest statement.pdf
Copyright License Agreement	64954-Copyright license agreement.pdf
Peer-review Report	64954-Peer-review(s).pdf
Scientific Misconduct Check	64954-Scientific misconduct check.pdf
Scientific Editor Work List	64954-Scientific editor work list.pdf
CrossCheck Report	64954-CrossCheck report.pdf